Scarica l'app Stockscreener
14.57
7.61%
1.30
Panoramica
Notizia
Cronologia dei prezzi
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$13.27
Aprire:
$11.06
Volume 24 ore:
95,013
Relative Volume:
107.72
Capitalizzazione di mercato:
$19.42M
Reddito:
$6.67M
Utile/perdita netta:
$-47.55M
Rapporto P/E:
-9.7133
EPS:
-1.5
Flusso di cassa netto:
$-17.44M
1 W Prestazione:
+2,693%
1M Prestazione:
+2,693%
6M Prestazione:
+2,693%
1 anno Prestazione:
+2,693%
Intervallo 1D:
$11.06
$15.81
Intervallo di 1 settimana:
$11.06
$19.32
Portata 52W:
$11.06
$19.32
Crescent Biopharma Inc Stock (CBIO) Company Profile
Nome
Crescent Biopharma Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta CBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
14.50 | 19.42M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.61 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.13 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.36 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
539.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
253.47 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-11 | Iniziato | Noble Capital Markets | Outperform |
| 2024-07-26 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-22 | Iniziato | CapitalOne | Overweight |
| 2021-11-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-04-29 | Ripresa | Stephens | Overweight |
| 2021-02-10 | Iniziato | Piper Sandler | Overweight |
| 2020-05-21 | Iniziato | Raymond James | Outperform |
| 2019-11-14 | Iniziato | ROTH Capital | Buy |
| 2019-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-05 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-04 | Iniziato | Oppenheimer | Outperform |
| 2018-12-18 | Iniziato | H.C. Wainwright | Buy |
| 2018-02-12 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Reiterato | Chardan Capital Markets | Buy |
| 2017-12-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Iniziato | Chardan Capital Markets | Buy |
| 2017-06-06 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-07-26 | Iniziato | SunTrust | Buy |
| 2016-06-30 | Iniziato | Rodman & Renshaw | Buy |
| 2015-03-17 | Reiterato | Stifel | Buy |
Mostra tutto
Crescent Biopharma Inc Borsa (CBIO) Ultime notizie
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Massive $200M Biotech Deal: Crescent Biopharma Secures Funding for Cancer Breakthrough Pipeline - Stock Titan
Crisis as catalyst: From Chernobyl evacuation to biotech innovation - BioXconomy
Gyre Therapeutics announces first doing in Phase 1 trial of F230 - TipRanks
How To Trade (GYRE) - news.stocktradersdaily.com
Is Costco's BNPL Push a Catalyst for Big-Ticket E-Commerce? - The Globe and Mail
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Hemophilia with Inhibitor Market Statistics Expected - openPR.com
A.I. Drone Operations Flourishing as Global Quantum Computing Market Expected to Reach $5.3 Billion By 2029 - The Globe and Mail
Forge Resources Announces Closing of Further Interest to 80% in Fully Permitted Coal Project, Colombia - The Globe and Mail
Quantum Computing Technology Evolving as Larger Scale of Applications & Uses Skyrockets - The Globe and Mail
AI Analyst Flags Key Risks and Upside for Nvidia Ahead of Earnings - The Globe and Mail
Prediction: SoundHound AI Stock Will Beat the Market. Here's Why. - The Globe and Mail
Zacks Investment Ideas feature highlights: CyberArk, Lam Research and monday.com - The Globe and Mail
(GYRE) Long Term Investment Analysis - news.stocktradersdaily.com
SBAC Stock Rises 12% Year to Date: Will the Trend Continue? - The Globe and Mail
GYRE Trading Resumes After Temporary Halt | GYRE Stock News - GuruFocus
Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility - GuruFocus
Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility | GYRE Stock News - GuruFocus
Factor Investing in Focus: What ETFs Say About Market Direction - The Globe and Mail
Is Navitas Semiconductor Stock a buy After Nvidia Enters the Room? - The Globe and Mail
Where Will Rigetti Computing Be in 3 Years? - The Globe and Mail
Here's How I'd Invest $10,000 Today - The Globe and Mail
How the (GYRE) price action is used to our Advantage - news.stocktradersdaily.com
Barclays Reaffirms Their Hold Rating on Floor & Decor Holdings (FND) - The Globe and Mail
Why JD.com Stock Slumped on Thursday - The Globe and Mail
Will Crimson Data Add Shine To Catalyst Biosciences? - RTTNews
Where are the Opportunities in (GYRE) - news.stocktradersdaily.com
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - BioSpace
Press Release Distribution & PR Platform - ACCESS Newswire
Corteva Invests in Desert Bacteria Startup That Boosted Crop Yields 15% Across 800,000 Acres - Stock Titan
Puna Bio receives investment from Corteva Catalyst - Yahoo Finance
Carnival Is Down 27% in 2025. Is This a Once-in-a-Lifetime Buying Opportunity Before the Stock Goes Parabolic? - The Globe and Mail
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025 (NASDAQ:DRUG) - Seeking Alpha
AbCellera: Attractively Priced But A Catalyst Is Needed - Seeking Alpha
Spotting Winners: Teleflex (NYSE:TFX) And Surgical Equipment & ConsumablesSpecialty Stocks In Q4 - The Globe and Mail
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Geode Capital Management LLC - Defense World
Wellington Management Group LLP Sells 8,034 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
(GYRE) Proactive Strategies - news.stocktradersdaily.com
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Sei Investments Co. - Defense World
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha
Gyre Therapeutics announces NMPA approval for trial on pirfenidone - TipRanks
Business - isStories
Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351 - TipRanks
Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win - Investor's Business Daily
GyreIntriguing Upcoming Data Catalyst, But I'm Still On Sidelines (NASDAQ:GYRE) - Seeking Alpha
3 Reasons to Avoid LUMN and 1 Stock to Buy Instead - The Globe and Mail
Hemophilia B Pipeline 2024: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharma - Barchart
Avidity Biosciences Shares Tumble Despite Trial Success - TipRanks
How to Take Advantage of moves in (GYRE) - Stock Traders Daily
Crescent Biopharma Inc Azioni (CBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Crescent Biopharma Inc Azioni (CBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10% Owner |
Aug 07 '24 |
Sale |
0.18 |
61,488 |
11,197 |
6,578,438 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 05 '24 |
Sale |
0.19 |
164,523 |
30,996 |
6,695,658 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 06 '24 |
Sale |
0.18 |
55,732 |
10,188 |
6,639,926 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 02 '24 |
Sale |
0.20 |
286,200 |
57,354 |
6,860,181 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 01 '24 |
Sale |
0.22 |
63,564 |
13,743 |
7,146,381 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 30 '24 |
Sale |
0.22 |
756,835 |
167,185 |
7,209,945 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 29 '24 |
Sale |
0.24 |
363,949 |
85,637 |
7,966,780 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 26 '24 |
Sale |
0.24 |
258,335 |
62,440 |
8,330,729 |
| Rock Edwin | Chief Medical Officer |
Jun 20 '24 |
Buy |
0.25 |
190,000 |
48,108 |
565,403 |
| Rock Edwin | Chief Medical Officer |
Jun 21 '24 |
Buy |
0.27 |
115,000 |
30,716 |
680,403 |
1.59%
0.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):